## Changes in Major Financial Data [2024/9]

1 Consolidated performance outline

Oorisondated p	or ror marie								
		2Q				FY			Forecast
		23/9	24/9	20/3	21/3	22/3	23/3	24/3	25/3
Net sales	(million yen)	36,794	40,809	60,595	59,976	66,848	77,962	76,895	82,000
Operating profit	(million yen)	-120	2,105	4,916	5,179	4,684	4,739	1,617	4,450
margin	(%)	-0.3%	5.2%	8.1%	8.6%	7.0%	6.1%	2.1%	5.4%
Ordinary profit	(million yen)	1,701	1,064	4,583	5,320	6,529	5,675	3,710	3,650
margin	(%)	4.6%	2.6%	7.6%	8.9%	9.8%	7.3%	4.8%	4.5%
Profit attributable									
to owners of	(million yen)	958	575	3,440	3,818	4,663	3,147	1,511	2,350
parent									
margin	(%)	2.6%	1.4%	5.7%	6.4%	7.0%	4.0%	2.0%	2.9%

2 Net sales by segments

INEL Sales by S	egillelite								
		2Q				FY			Forecast
		23/9	24/9	20/3	21/3	22/3	23/3	24/3	25/3
Net sales	(million yen)	36,794	40,809	60,595	59,976	66,848	77,962	76,895	82,000
VCCS			Ì						·
(Vehicle Communication	(million yen)	26,491	27,714	38,748	37,004	39,706	46,089	55,583	55,600
Comfort & Safety)									
Composition ratio	(%)	72.0%	67.9%	64.8%	62.2%	59.9%	59.1%	72.3%	62.8%
CTC									
(Circuit Testing	(million yen)	6,188	7,467	12,832	13,242	17,625	22,374	12,585	15,300
Connector)	4	40.00/	40.00/	0.4.00/	00.40/	00.40/	00 70/	40.40/	0.4.00/
Composition ratio	(%)	16.8%	18.3%	21.2%	22.1%	26.4%	28.7%	16.4%	21.6%
FC/MD			- 404	0.400	0.404	0.40=	0.054	0.070	40.000
(Fine Connector) /	(million yen)	3,903	5,461	8,486	9,424	9,125	9,051	8,373	10,800
(Medical Device)	()	40.00/	40.40/	44.00/	45.70/	40.70/	44.00/	40.00/	45.00/
Composition ratio	(%)	10.6%	13.4%	14.0%	15.7%	13.7%	11.6%	10.9%	15.2%
Incubation Center	(million yen)	207	163	515	287	375	430	345	300
Composition ratio	(%)	0.6%	0.4%	0.9%	0.5%	0.6%	0.6%	0.4%	0.4%
Other	(million yen)	4	2	11	16	15	16	7	0
Composition ratio	(%)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

## 3 Overseas sales

	2Q				FY					
	23/9	24/9	20/3	21/3	22/3	23/3	24/3			
For Europe and North (million yen) America	14,389	16,034	17,934	17,272	19,466	26,400	30,456			
For Asia (million yen)	11,609	12,711	22,293	23,116	28,801	32,980	23,835			
Overseas sales total (million yen)	25,999	28,745	40,228	40,389	48,268	59,381	54,292			
Percentage of net sales	70.7%	70.4%	66.4%	67.3%	72.2%	76.2%	70.6%			

4 Capital expenditures

		2Q			FY					
		23/9	24/9	20/3	21/3	22/3	23/3	24/3	25/3	
Total	(million yen)	3,057	1,653	3,625	4,430	5,092	5,448	4,741	4,100	

5 Depreciation

_										
	2Q				FY					Forecast
			23/9	24/9	20/3	21/3	22/3	23/3	24/3	25/3
	Total	(million yen)	1,960	1,974	2,706	2,987	3,302	3,833	4,013	4,000

6 Changes in financial data

		2Q	2Q			FY				
	Minimum 10	23/9	24/9	20/3	21/3	22/3	23/3	24/3	25/3	
	Operating profit margin(%)	-0.3%	5.2%	8.1%	8.6%	7.0%	6.1%	2.1%	5.4%	
	Operating profit growth rate(%)	-103.4%	-	62.4%	5.4%	-9.6%	1.2%	-65.9%	175.1%	
	ROE(%)	2.0%	1.2%	13.5%	12.2%	11.6%	6.9%	3.1%	4.7%	
	ROIC(%)	-	-	-	-	-	5.8%	1.8%	4.9%	
Ratio to capital adequacy(%)		65.1%	65.2%	55.1%	63.6%	66.2%	66.7%	65.8%	65.2%	
Basic earnings per share(yen)		41.13	24.68	169.85	184.55	202.28	135.01	64.86	100.81	
Dividend per share(yen)		22.00	24.00	30.00	36.00	40.00	50.00	44.00	48.00	
Pa	yout ratio(%)	53.5%	97.2%	17.7%	19.5%	19.8%	37.0%	67.8%	47.6%	

<sup>\*</sup> The contents described in this document are based on various assumptions and do not commit or guarantee the future forecast values as stated.

